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ABSTRACT 1 
Aims: The genetic cause of cardiac conduction system disease (CCSD) has not been fully elucidated. 2 
Whole-exome sequencing (WES) enables the detection of a variety of genetic variants; however, the 3 
identification of pathogenic variants remains a challenge.  We aimed to identify pathogenic or likely 4 
pathogenic variants in patients with CCSD by using WES and 2015 American College of Medical 5 
Genetics and Genomics (ACMG) standards and guidelines as well as evaluating the usefulness of 6 
functional studies for determining them. 7 
Methods and Results: We performed WES of 23 probands diagnosed with early-onset (<65 years) 8 
CCSD and analyzed 117 genes linked to arrhythmogenic diseases or cardiomyopathies.  We focused 9 
on rare variants (minor allele frequency < 0.5%) that were absent from the in-house WES data.  We 10 
used 2015 ACMG standards and guidelines to classify these variants.  Five probands had pathogenic 11 
variants in the EMD and LMNA genes.  To evaluate the functional change of an LMNA c.339dupT, 12 
we sought to generate a knock-out zebrafish with CRISPR-mediated insertions or deletions of the 13 
human LMNA homolog, lmna in zebrafish.  The mean heart rate and conduction velocities of the 14 
CRISPR/Cas9-injected embryos and F2 generation embryos with homozygous deletions were 15 
significantly decreased compared with those of the controls.  Twenty-four variants of uncertain 16 
significance were identified in 14 probands.  Cellular electrophysiological study showed that 3 17 
variants in the KCNA5, KCNH2, and SCN5A genes, and 4 variants in the SCN10A genes damaged each 18 
gene, which resulted in the change of the clinical significance of these variants from “Uncertain 19 
significance” to “Likely pathogenic” in 5 probands.   20 
Conclusions: Of 23 probands with CCSD, we successfully identified pathogenic or likely pathogenic 21 
variants in 10 probands (43%).  Functional analyses of a cellular electrophysiological study and 22 
CRISPR/Cas9-mediated gene knock-out in zebrafish might be useful for determining the 23 
pathogenicity of rare variants in patients with CCSD. 24 
Translational Perspective: Whole-exome sequencing (WES) may be helpful in determining the 25 
causes of cardiac conduction system disease (CCSD), however, the identification of pathogenic 26 
variants remains a challenge.  We performed WES of 23 probands diagnosed with early-onset CCSD, 27 
and identified 12 pathogenic or likely pathogenic variants in 10 of these probands (43%) according to 28 
the 2015 ACMG standards and guidelines.  In this context, functional analyses of a cellular 29 
electrophysiological study and CRISPR/Cas9-mediated gene knock-out in zebrafish might be useful 30 
for determining the pathogenicity of rare variants, and SCN10A may be one of the major 31 
development factors in CCSD.  32 
  33 
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1. Introduction 1 
Bradyarrhythmia is a common clinical finding and can be usually due to a physiologic reaction, 2 
pharmacotherapy, or advanced age.  Patients with bradyarrhythmia may present with syncope, 3 
symptoms of heart failure, and rarely sudden cardiac death.  The cardiac conduction system 4 
consists of the sinus node, atrio-ventricular node, and His-Purkinje system.  Bradyarrhythmia can be 5 
categorized on the level of disturbances in the hierarchy of this system and includes sinus node 6 
dysfunction and atrioventricular conduction disturbances or blocks.1 7 
The pathophysiologic mechanisms underlying cardiac conduction-system disease (CCSD) 8 
are divided into acquired or inherited causes.  Several studies showed genetic variants associated 9 
with CCSD linked to either structurally normal heart diseases (HCN4, CACNA1G, CACNA1D, SCN5A, 10 
SCN1B, Cx40, KCNJ2, TRPM4, KCNK17, ANK2, CAV3, CASQ2, and RYR2 genes) or structural heart 11 
diseases (MYH6, PRKAG2, Nkx2.5, Tbx5, LMNA, EMD, SGOL1, and LAMP-2 genes).1-5  Thus, high-12 
throughput sequencing (HTS) may be helpful in determining the causes of CCSD because of their 13 
comprehensiveness.6, 7  However, few studies exist whether whole exome sequencing is useful for 14 
detecting causative variants in patients with early-onset CCSD. 15 
Advancement of HTS has identified lots of putative variants associated with inherited cardiac 16 
disease.  However, determining true pathogenicity of targeted diseases is still a major challenge.8  17 
In 2015, the American College of Medical Genetics and Genomics (ACMG), the Association for 18 
Molecular Pathology (AMP), and the College of American Pathologists reported updated standards 19 
and guidelines for the classification of sequence variants using criteria informed by expert opinion 20 
and empirical data.9  This guideline consists of 28 criteria based on different sources of data 21 
including population data, computational and predictive data, functional data, segregation data, de 22 
novo data, and allelic data.  Of these criteria, functional studies could be one of the powerful tools 23 
in support for disease pathogenicity.9  The gold standard for the functional analysis of ion-channel 24 
variants is an electrophysiological measurement using a patch-clamp method in cell expression 25 
systems10 and a simulation study with mathematical models of human cardiomyocytes.  In addition, 26 
zebrafish is an emerging model for studying cardiac diseases, including cardiac arrhythmia.11-16  27 
Moreover, CRISPR/Cas9-mediated gene knock-out in zebrafish can facilitate high-throughput screens 28 
for phenotypic effects with high levels of on-target efficiency and relatively off-target 29 
modifications.17, 18  However, in vivo zebrafish assay using CRISPR/Cas9 systems has not been fully 30 
established for interpreting pathogenicity of human rare variants associated with CCSD.  31 
Here, we assessed 23 probands diagnosed with early-onset CCSD with pacemaker 32 
implantation (PMI) or a family history of PMI.  We exome-sequenced for these patients to identify 33 
putative variants that could cause a CCSD.  Then, we performed functional studies to re-classify 34 
guideline-based pathogenicity for these variants, using a patch-clamp method in heterologous 35 
expression systems, a simulation study, and the combination of CRISPR/Cas9 systems with zebrafish.  36 
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2. Methods 1 
All data and supporting materials have been provided in the published article.  An expanded 2 
Methods section is available in the Online Supplementary Data. 3 
 4 
2.1 Study patients 5 
The study conformed with the principles outlined in the Declaration of Helsinki and was approved by 6 
the Ethics Committee for Medical Research at our institution.  All study patients provided written 7 
informed consent before registration. 8 
The study patients were recruited from multiple hospitals in Japan.  Early-onset CCSD was 9 
defined as bradyarrhythmia occurring in individuals aged <65 years, who showed an atrioventricular 10 
(AV) block and/or a sick sinus syndrome (SSS) with PMI or a family history of PMI as described in the 11 
Online Supplementary Data.  In addition, we used DNA-sequencing data of 102 control subjects 12 
without electrocardiogram (ECG) abnormality. 13 
 14 
2.2 DNA isolation and whole-exome DNA sequencing 15 
WES was performed using the Illumina HiSeq platform (Illumina, San Diego, CA, USA) as described in 16 
the Online Supplementary Data.  After the standard quality control, we selected only the variants 17 
that were absent in the in-house WES data from 102 control individuals without early-onset CCSD.  18 
Of those, we extracted the variants in 117 candidate genes linked to arrhythmogenic disorders or 19 
cardiomyopathy as a single gene disorder for further analyses (Supplemental Table 1). 20 
 21 
2.3 Pathogenicity of candidate variants 22 
We interpreted the sequence variants using 2015 ACMG standards and guidelines, which provided 23 
criteria for the classification of pathogenic or likely pathogenic variants.9  Each pathogenic criterion 24 
is weighted as very strong (PVS1), strong (PS1–4), moderate (PM1–6), or supporting (PP1–5).  Rare 25 
variants were defined as those with a minor allele frequency <0.5% in East Asians of the Human 26 
Genetic Variation Database (HGVD) version 2.3 and the Genome Aggregation Database (gnomAD) 27 
version 2.0.2.  Variants that were absent from these databases were considered PM2.  We 28 
selected protein-truncating variants (PTVs) in known genes associated with CCSD (PVS1), or rare 29 
missense variants registered as pathogenic or disease-causing mutations associated with CCSD in the 30 
ClinVar and Human Gene Mutation Database (HGMD) (PP5)  All variants were annotated by the 31 
Variant Effect Predictor version 82 and referred following in silico damaging scores: MetaSVM for 32 
missense variants; LOFTEE for PTVs; and CADD for all variants.19  CADD score of 15 indicated that 33 
the variant is predicted to be among the 15% most deleterious substitutions that can occur in the 34 
human genome.  When multiple lines of these in silico prediction algorithms supported a 35 
deleterious effect on the gene, the supporting pathogenic evidence of PP3 was assigned.  We 36 
further sought to determine the relationship between the clinical phenotype (bradyarrhythmia) and 37 
the genotype for probands and their relatives in whom a variant was identified (PP1 or PP4).  These 38 
segregation analyses were performed in the family members as much as possible.  If the missense 39 
variants are common causes of the disorder and the gene has very few benign variants, then a 40 
missense variant in this gene can be supporting evidence for pathogenicity (PP2).  Functional 41 
studies used cellular electrophysiological analysis, mathematical modeling, and simulations, and 42 
CRISPR/Cas9 mediated gene knock-out in zebrafish to confirm the pathogenicity of the detected 43 
variants (PS3 or BS3).  For a given variant, we selected the criteria based on the evidence observed 44 
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for the variant.  The criteria are then combined according to the scoring rules to choose a 1 
classification from the 5-tier system.9 2 
 3 
2.4 CRISPR-mediated deletions of the human LMNA ortholog, lmna, in zebrafish 4 
All zebrafish experiments have been approved by Institutional Animal Care and Use Committee 5 
(protocol# BWH 2016N000276), which is certified by the Association for Assessment and 6 
Accreditation of Laboratory Animal Care.  Zebrafish euthanasia was performed following NIH 7 
(https://oacu.oir.nih.gov/animal-research-advisory-committee-guidelines) and American Veterinary 8 
Medical Association guidelines using an overdose of Tricaine (M-222 or 3-aminobenzoic acid ethyl 9 
ester) in combination with hypothermic shock.  10 
The gene editing in zebrafish with CRISPR/Cas9 was conducted to evaluate detected PTV in 11 
the LMNA gene from a patient with early-onset CCSD as described in the Online Supplementary 12 
Data. 13 
Cardiac phenotypes were scored at 48 and 72 hpf, and genomic DNA was prepared from 10 14 
individuals for Sanger sequencing as described in the Online Supplementary Data.  The heart rate 15 
was visually counted at 48 hpf by using a stereomicroscope.  Cardiac function was evaluated at 48 16 
hpf by using video microscopy with an Axioplan (Zeiss) upright microscope.  Voltage mapping was 17 
recorded on isolated 72 hpf zebrafish hearts.20   18 
Mosaic founders (F0) were raised and were outcrossed to a wild-type line at the age of 3 19 
months (Supplemental figure 1).  Heterozygous F1 generation fishes with same lmna mutation were 20 
incrossed, and cardiac phenotypes for F2 embryos were evaluated as stated above.  Each F2 21 
embryo was genotyped after evaluation of the cardiac phenotype to distinguish between 22 
heterozygous and homozygous carriers. 23 
 24 
2.5 Plasmid constructs and transfection of mammalian cell lines 25 
Mutant cDNAs were constructed by an overlap extension strategy or using a QuikChange XL Site-26 
Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) as described in the Online 27 
Supplementary Data.  Mammalian cells were transfected with the cDNA encoding potassium or 28 
sodium channels and green fluorescent protein (GFP) as described in the Online Supplementary 29 
Data.  Cells displaying green fluorescence 48–72 h after transfection were subjected to 30 
electrophysiological analysis. 31 
 32 
2.6 Electrophysiology and data analysis 33 
Potassium or sodium currents were studied using the whole-cell patch clamp technique with an 34 
amplifier, Axopatch-200B (Molecular Devices, Sunnyvale, CA, USA), at room temperature as 35 
described in the Online Supplementary Data. 36 
  37 
2.7 Mathematical modeling and simulations 38 
With mathematical models of human ventricular myocytes21 and rabbit peripheral sinoatrial node 39 
(SAN) cells,22 effects of the changes in kinetic behavior of IKr and INa on the mid-myocardial action 40 
potential configuration of the ventricular myocyte model and pacemaker activity of the peripheral 41 
SAN cell model connected to the atrial membrane model via the gap junction conductance were 42 
evaluated. Dynamic behaviors of the model cell were determined by solving a system of nonlinear 43 
ordinary differential equations numerically.  Numerical integration was performed on Workstation 44 
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HP xw9400 with MATLAB 7.5 (The MathWorks, Inc., Natick, MA, USA).  The numerical algorithms 1 
available as a MATLAB ODE solver, ode15s (a variable time-step numerical differentiation approach 2 
selected for its suitability to stiff systems), were used. 3 
 4 
2.8 Statistical analysis  5 
Pooled electrophysiological data were expressed as mean ± standard error.  Two-tailed Student’s t-6 
test was used for the single comparisons between the two groups.  One-way analysis of variance, 7 
followed by a Bonferroni post hoc test, was used to analyze data with equal variance among three or 8 
more groups.  A P<0.05 was considered statistically significant. Statistical analysis was performed 9 
using JMP Pro 11.0.0 (SAS Institute Inc., NC, USA) and Origin 2018 (OriginLab, Northampton, MA, 10 
USA). 11 
  12 
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3. Results 1 
3.1 Clinical characteristics and molecular genetic analysis of the study cohort 2 
The mean age of the study participants was 40 ± 16 years at the diagnosis of CCSD (Table 1).  Of 23 3 
subjects, 12 were women (52%), 13 had SSS (57%), and 17 (74%) had AV block in one first-degree 4 
relative, and 18 (78%) underwent PMI.  Echocardiographic data revealed a normal mean ejection 5 
fraction.  Atrial fibrillation (AF) and muscular disease were complicated in 12 (52%) and 2 (10%) 6 
subjects, respectively.  7 
The genetic analysis showed that 5 PVS1 null variants were identified in the EMD and LMNA 8 
genes where loss of function is a known pathogenicity for CCSD (Table 2).  These PTVs were absent 9 
from the controls in gnomAD or HGVD (PM2).  Both CADD and LOFTEE indicated a deleterious effect 10 
of these PTVs on each gene (PP3) (Supplemental Table 2).  ClinVar or HGMD classified EMD p. 11 
W226X, LMNA c. 1489-2A>G, and LMNA p. R321X into pathogenic, or disease causing variants (PP5).  12 
In addition to these 5 PTVs, 1 PTV and 14 missense variants were absent from the controls (PM2), 13 
1PTV and 23 missense variants were considered as deleterious by in silico predictive algorithms 14 
(PP3), and 4 missense variants were classified as disease causing variants by HGMD (PP5) (Table 2 15 
and Supplemental Table 2). 16 
  17 
3.2 Clinical characteristics of patients with PTVs in the EMD or LMNA gene 18 
We identified 2 PTVs in the EMD gene and 3 PTVs in the LMNA gene (Table 2).  Two patients 19 
harboring PTVs in the EMD gene were diagnosed with CCSD at the age of 33 and 17 years, 20 
respectively.  They showed AV block and AF in addition to muscular dystrophy, and underwent 21 
PMI23 (Table 3).  With regard to patient 1 with EMD p.W226X, we previously reported an Emery–22 
Dreifuss muscular dystrophy (EDMD) family including 16 carriers (7 men and 9 women) with EMD 23 
p.W226X.  EDMD caused by the EMD gene mutation is associated with X-linked recessive 24 
inheritance.  All of the 7 male carriers had cardiac involvement, and their first cardiac manifestation 25 
occurred at age 10 to 37 years (mean age, 20.9 years) (PP1).23  In patient 2, the segregation variant 26 
was confirmed in the EMD gene (p. Q222X).  Proband’s parents did not have this variant which was 27 
classified as de novo mutation (PS2).  28 
Three patients harboring PTVs in the LMNA gene were diagnosed with CCSD at the age of 29 
39, 23, and 44 years, respectively.  Patient 3 with LMNA K114XfsX1 was a 55-year-old woman (Table 30 
3).  Her ECG showed first-degree AV block at age 39 years and sinus arrest at age 41 years.  She 31 
had a family history of SCD and PMI.  She received PMI at age 42 years and developed AF at 47 32 
years.  Echocardiogram showed low normal LV systolic function.  Patient 4 with LMNA 1489-2A>G 33 
was a 23-year-old man (Table 3).  His mother died suddenly due to ventricular fibrillation at the age 34 
of 50 years.  His ECG showed AF and complete AV block, and received ICD therapy.  35 
Echocardiogram showed normal LV systolic function.  Patient 5 with LMNA R321X was a 44-year-old 36 
woman (Table 3).  She had a family history of SCD and PMI.  Her ECG showed paroxysmal AF at age 37 
32 years and first-degree AV block at age 43 years.  She received ICD therapy at the age of 44 years 38 
old.  Echocardiogram showed normal LV systolic function. 39 
PTVs in the EMD and LMNA genes could be defined as pathogenic on the basis of “1 very 40 
strong (PVS1) and 1 Moderate (PM2) and 1 supporting by the guideline (PP1, PP3, or PP5) (Table 2). 41 
 42 
3.3 Functional studies of PTV in the LMNA gene using zebrafish 43 
We studied the usefulness of in vivo zebrafish assay using CRISPR/Cas9-mediated gene knock-out for 44 
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interpreting PTVs associated with CCSD.  We sought to confirm the functional effect of one of PTVs, 1 
c. 339dupT, p. K114XfsX1 in the LMNA gene.  The human LMNA homolog, lmna, in zebrafish is only 2 
one copy, and the percentage of the orthologous sequence matching the human sequence is 63.13%. 3 
The target site was selected around the equivalent lmna site of the human LMNA 4 
c.339dupT (Figure 1A).  Subsequently, sg RNA and Cas9 protein or only sg RNA was microinjected 5 
into one-cell stage zebrafish embryos.  At 48 hpf after the microinjection, the appearance of both 6 
embryos looked similar (Supplemental Figure 2A).  Genomic DNA was prepared from 10 individuals, 7 
and Sanger sequencing showed a variety of mutations in CRISPR/Cas9-injected embryos 8 
(Supplemental Figure 2A).  At 48 hpf, the HR of zebrafish embryo was visually counted under 9 
upright microscope.  The mean HR of the CRISPR/Cas9-injected embryos significantly decreased 10 
compared with those of CRISPR-only injected or non-injected embryos (Supplemental Figure 2B).  11 
Voltage mapping on isolated 72 hpf zebrafish hearts showed that the mean conduction velocities of 12 
the ventricle (mm/s) were significantly decreased in the CRISPR/Cas9-injected embryos compared 13 
with CRISPR-only injected embryos (8.0 ± 1.2 vs.16.8 ± 2.6; P<0.01) (Supplemental Figure 2C). 14 
We also evaluated F2 zebrafish embryos.  Sequencing analysis of F1 fish after outcross 15 
between mosaic founders (F0) and wild-type fishes showed various truncating indels.  Of 10 16 
genotyped F1 fish, 6 had heterozygous lmna c. 316_319 del GTGC, p. E108TfsX5, which caused a 17 
premature stop codon (1 male and 5 females).  Cardiac phenotypes for F2 embryos after incross 18 
between these heterozygous fishes were evaluated.  Subsequently, each F2 embryo was genotyped 19 
after evaluation of the cardiac phenotype to distinguish between heterozygous and homozygous 20 
carriers.  The appearance of both embryos (lmna +/+ and lmna del/del) looked similar (Figure 1B).  21 
The mean HR of lmna del/del significantly decreased compared with those of lmna +/+ (Figure 2A).  The 22 
evaluation of cardiac function using video microscopy showed that the mean stroke volume, mean 23 
cardiac output, and the mean fractional area change of lmna del/del significantly increased compared 24 
with those of lmna +/+ (Table 4 and Figure 2B).  Voltage mapping on isolated 72 hpf zebrafish hearts 25 
showed that mean conduction velocities of both atrioventricular canal and ventricle were 26 
significantly decreased in lmna del/del compared with lmna +/+.  In contrast, those of atrium were 27 
comparable between these two groups (Table 4 and Figure 2C and D). 28 
 29 
3.4 Clinical characteristics of a patient harboring both two rare missense variants in KCNH2 and 30 
SCN5A and functional properties of the variants 31 
Furthermore, we sought to define the functional effect of 2 rare missense variants classified as 32 
“uncertain significance” by the guideline in KCNH2 and SCN5A genes. 33 
Patient 7 with SCN5A P1824A and KCNH2 R269W was a 47-year-old woman.24  Her ECG 34 
showed SA block, AV block, and marked QT prolongation (HR 56/min, QTc 0.56 s).  Holter ECG 35 
monitoring revealed a 4.5 seconds pause with transient loss of consciousness.  She had a family 36 
history of PMI and considered to be an indication for PMI.  Echocardiogram showed normal LV 37 
systolic function. 38 
HEK293 cells were transiently transfected with vectors expressing wild-type or P1824A 39 
cDNA and the human beta1 subunit cDNA in combination with a bicistronic plasmid encoding GFP.  40 
Compared with the wild-type Nav1.5 channel, P1824A significantly reduced the peak sodium current 41 
density.  The maximum peak current density of P1824A was −846 ± 131 pA/pF, which was 42 
significantly smaller than −1485 ± 186 pA/pF for wild-type (P<0.05) (Figures 3A, 3C and Table 5).  No 43 
difference was found in persistent sodium current between wild-type (0.50% ± 0.07% of peak) and 44 
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P1824A (0.30% ± 0.07% of peak) (Figure 3B).  The voltage dependence of steady-state activation of 1 
P1824A was significantly shifted in depolarizing (+ 5.7 mV) directions (Figure 3D and Table 5).  No 2 
significant difference was observed in the voltage dependence of steady-state fast inactivation 3 
(Figure 3D). 4 
Then, we transiently expressed Kv11.1 channels of wild-type, R269W, and wild-type + 5 
R269W in cultured mammalian CHO-K1 cells for whole-cell voltage clamp measurements (Figure 3E).  6 
Electrophysiological studies showed that the maximum tail current of R269W was 41.3 ± 7.4 pA/pF, 7 
which was significantly smaller than 84.2 ± 11.2 pA/pF for wild-type (P<0.05) (Figure 3F and Table 5).  8 
The maximum tail current of wild-type + R269W was 75.7 ± 18.7 pA/pF, which was comparable to 9 
that of wild-type alone.  No significant difference in activation and deactivation kinetics was 10 
observed among three channels (Figures 3G and H, Table 5).  The steady-state inactivation was 11 
shifted in its voltage dependence to a negative potential of −80.8 ± 8.6 mV for R269W and −63.0 ± 12 
4.8 mV for wild-type + R269W compared with that of wild-type (−50.1 ± 4.5 mV) (R269W vs. wild-13 
type, P<0.05) (Figure 3G and Table 5).  14 
Simulation study showed that the mutational changes in the conductance and 15 
activation/deactivation/inactivation kinetics of IKr and INa prolonged the mid-myocardial action 16 
potential duration by 58% in the patient model of human ventricular myocytes and led to the 17 
formation of early afterdepolarizations when IKr was blocked by 7% (Figures 4A and B).  The study 18 
also showed that INa and IKr during spontaneous action potentials of the patient peripheral SAN 19 
model were much smaller than those of the normal model (Figure 4C).  Electrotonic modulations of 20 
the atrial myocyte caused arrhythmic dynamics (bradyarrhythmia) and cessation of pacemaker 21 
activity in the patient SAN model, but not in the normal one. 22 
 23 
3.5 Clinical characteristics of a patient with rare PTV and missense variants in SCN10A gene, and 24 
electrophysiological studies for these variants. 25 
Finally, we found one PTV and 5 rare missense variants classified as “uncertain significance” by the 26 
guideline in the SCN10A gene in 4 of 23 patients with CCSD (Table 3).  Patient 6 with SCN10A 27 
R1263X showed paroxysmal AF at age 49 years and had a sinus pause of 3.6 s following termination 28 
of AF on his monitoring ECG at age 51 years.  He received pacemaker therapy.  He also had a rare 29 
variant, KCNA5 T527M.  We previously assessed the functional property of KCNA5 T527M 30 
channel.10  Cellular electrophysiological studies showed that the activating current density for 31 
T527M was significantly larger than that for wild-type.  The T527M mutant displayed a negative 32 
voltage shift in the normalized activation curve.  Patient 8 with SCN10A I1482V was diagnosed as 33 
SSS, AV block, and AF at age 42 years.  She received a pacemaker therapy at the age of 56 years old.  34 
Patient 9 with SCN10A D1819Y and M1373R had AV block at age 31 years.  She developed syncope 35 
at age 36 years and received pacemaker therapy.  Patient 10 with SCN10A F507L and G805S was a 36 
17-year-old man who had SSS and received pacemaker therapy.  Echocardiogram of these 4 37 
patients showed normal LV systolic function. 38 
ND7/23 cells were transiently transfected with vectors expressing wild-type, G805S, 39 
R1263X, M1373R, I1482V, or D1819Y SCN10A cDNA in the plasmid encoding GFP.  Figure 5A shows 40 
representative current traces recorded for these wild-type and rare variant Nav 1.8 channels.  41 
Neither R1263X nor M1373R generated sodium currents, whereas wild-type, G805S, I1482V, and 42 
D1819Y generated sodium currents.  Compared with the wild-type, G805S and D1819Y decreased 43 
the peak sodium current density, and I1482V increased the current density.  The maximum peak 44 
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current density of I1482V was −162.9 ± 30.3 pA/pF, which was significantly larger than −101.0 ± 8.9 1 
pA/pF for wild-type (P<0.05) (Figures 5A, B and Table 6).  The voltage dependence of steady-state 2 
activation of I1482V was significantly shifted by 8.9 mV in hyperpolarizing directions (Figure 5C and 3 
Table 6).  G805S variant caused a significant depolarizing shift (+ 4.5 mV) in the voltage-dependence 4 
of inactivation (Figure 5D and Table 6). 5 
 6 
3.6 Classification of rare variants in consideration of functional studies 7 
Above functional studies demonstrated that 8 rare variants in the KCNA5, KCNH2, SCN5A, SCN10A, 8 
and LMNA genes could have damaging effects on each target gene (PS3) (Table 2).  Of those, 7 9 
variants changed their clinical significance from “uncertain significance” to “likely pathogenic” when 10 
added the functional study results: “1 strong (PS3) and 1 Moderate (PM2)” or “1 strong (PS3) and 2 11 
supporting (PP3 and PP5) (Table 2). 12 
  13 
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4. Discussion 1 
In the present study, we analyzed 23 patients with CCSD for rare variants in arrhythmia and/or 2 
cardiomyopathy-related 117 genes using HTS.  Since functional studies contributed greatly to the 3 
determination of the precise pathogenicity of variants of unknown significance, we finally 4 
determined 5 pathogenic variants in 5 patients and 7 likely pathogenic variants in 5 patients 5 
according to 2015 ACMG standards and guidelines. 6 
This study provided some interesting findings.  First, we identified 2 PTVs in the EMD gene 7 
and 3 PTVs in the LMNA gene as pathogenic.  Also, we could confirm its pathogenicity by functional 8 
properties of one PTV in the LMNA gene using the CRISPR/Cas9-mediated zebrafish.  The EMD and 9 
LMNA genes are known to be the disease-causing genes of EDMD with manifestation as high-grade 10 
AV block.  The former is associated with X-linked recessive inheritance and the latter with 11 
autosomal dominant, autosomal recessive, and sporadic forms of EDMD.  Both genes encode 12 
nuclear envelope proteins.  EDMD is a genetically heterogeneous disorder characterized by early 13 
contractures, slowly progressive muscle wasting and weakness, and cardiomyopathy with conduction 14 
block.  Some patients present with conduction disturbances or atrial cardiomyopathy even when 15 
skeletal myopathy is absent and are possible candidates for these mutations. In terms of 16 
CRISPR/Cas9-mediated zebrafish analysis, it has been used as a useful in vivo model to assay the 17 
pathogenicity of human variants in familial cardiovascular diseases.25-27  Zebrafish has the 18 
advantage of transparency, low cost, and the ability to manipulate their genome efficiently.  19 
Zebrafish can gain a prominent role as the models of thousands of candidate disease-associated 20 
genes and alleles.28  The recent sequencing of zebrafish revealed that approximately 70% of human 21 
genes had functional homologs in zebrafish.28  We confirmed that the human LMNA homolog, 22 
lmna, in zebrafish is only one copy, and the percentage of the orthologous sequence matching the 23 
human sequence was 63.13%.  Namely, human pathogenesis of CCSD with the LMNA gene 24 
mutation could be modeled in zebrafish. 25 
Second, we could determine the pathogenicity of 7 rare ion channel variants with 26 
previously defined as “unknown significance” by two functional analyses, electrophysiological and 27 
simulation studies.  SCN5A P1824A and KCNH2 R269W were identified from the proband with SSS, 28 
AV block, and QT prolongation.24  Electrophysiological study demonstrated that both mutations 29 
showed loss-of -function.  A simulation study demonstrated that SCN5A P1824A might contribute to 30 
sinus node dysfunction.  The SCN5A gene encodes for the α-subunits of the voltage-gated Na+ 31 
channels (the Nav 1.5 channel), which is expressed in the conduction system and in the atrial regions 32 
surrounding the SAN and the atrio-ventricular node.29  In contrast, KCNH2 variant might contribute 33 
to both sinus node dysfunction and QT prolongation as clinical phenotype expressions.  The 34 
simulation study was useful in explaining the role of each variant in multiple disorders.  KCNA5 35 
T527M was identified from the proband with SSS and AF.  We previously reported that T527M 36 
showed a gain-of-function effect with an enhanced steady-state activation, which could result in 37 
susceptibility to AF and a sinus pause after the termination of AF.10  However, this variant is present 38 
at a relatively high frequency in East Asians which suggests either very low penetrance or only a 39 
modifying effect.  This proband also had likely pathogenic variant, SCN10A R1263X which showed 40 
loss of function of Nav 1.8 channel and may be associated with proband’s phenotype 41 
Third, we determined 4 likely pathogenic variants in 4 of 23 (17%) CCSD patients in the 42 
SCN10A gene.  A cellular electrophysiological study demonstrated that three variants (G805S, 43 
R1263X and M1373R) showed loss-of-function effects, and one variant (I1482V) showed gain-of-44 
12 
 
function effect.  The voltage-gated sodium channel alpha subunit, Nav1.8 is encoded by the SCN10A 1 
gene and is highly expressed in sensory neurons of dorsal root ganglia.  Several genome-wide 2 
association studies showed that SCN10A was associated with cardiac conduction.  A recent review 3 
showed how SCN10A variants promote dysfunctional conduction: the cardiomyocyte, enhancer, and 4 
neuronal hypotheses.30  CCSD caused by gain-of-function SCN10A rare variants may be explained 5 
through the neuronal hypothesis.  The neuronal hypothesis stipulates that SCN10A indirectly exerts 6 
an effect on cardiac conduction through intracardiac neurons.  SCN10A functions in cholinergic 7 
neurons to exert negative chronotropic and dromotropic effects on sinus and AV nodal tissues and 8 
modulates myocyte refractoriness.  Gain-of-function SCN10A rare variants might cause vagus nerve 9 
stimulation and cardiac conduction disturbance.  In contrast, the mechanism of causing CCSD by 10 
SCN10A loss-of-function rare variants is poorly understood.  One possibility is that the enhancer 11 
hypothesis may be associated with the onset of CCSD by these variants.  The enhancer hypothesis 12 
states that the cardiac enhancer located in Scn10a interacted with the promoter of Scn5a and was 13 
essential for Scn5a expression in murine cardiac tissue.  Further studies are needed to clarify the 14 
mechanism by which loss-of-function SCN10A rare variants modulate cardiac conduction and lead to 15 
development of bradycardia. 16 
 This study has several limitations.  First, only 117 genes linked to arrhythmogenic diseases 17 
or cardiomyopathies were examined for rare variants associated with CCSD.  Causative genes may 18 
be included in the remaining genes other than these 117 genes.  Second, of 13 probands with 19 
family history, familial aggregation and segregation analysis were performed only for two families 20 
with PTVs in the EMD gene.  However, we evaluated pathogenicity of rare variants by functional 21 
studies, including a patch-clamp method, a simulation study, and the CRISPR-mediated deletions of 22 
the lmna in zebrafish.  Third, approximately 30% of human genes did not have functional homologs 23 
in zebrafish.  Actually, we could not find a human EMD homolog in zebrafish and did not evaluate 24 
the functional change of an EMD protein-truncating variant using zebrafish model.  In addition, 25 
functional properties of most missense variants in non-ion-channel genes were not evaluated in this 26 
study. 27 
 28 
 29 
5. Conclusions 30 
Integrated HTS targeting 117 arrhythmia and cardiomyopathy-related genes with one-by-one various 31 
functional studies, we identified 12 pathogenic or likely pathogenic variants in 10 of 23 CCSD 32 
probands (43%): 5 probands harboring 5 pathogenic variants in genes encoding nuclear envelope 33 
proteins; 5 probands had at least one likely pathogenic variant in genes encoding ion channels.  34 
Notably, SCN10A may be one of the major development factors in CCSD. 35 
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Figure Legends 
Figure 1 Appearance and base sequence of F2 generation zebrafish embryo with lmna deletion 
mutation.   
(A) Multiple sequence alignment of human LMNA gene and zebrafish lmna gene.  (B) 
Representative images illustrating the morphology of 2 dpf wild-type and lmnadel/del mutants and 
Sanger sequence of lmna gene.  DSB, double-strand break; PAM, protospacer adjacent motif 
 
Figure 2 Functional studies of F2 zebrafish embryos with lmna deletion mutation.   
(A) Heart rate of lmna+/+ (n=15) and lmnadel/del mutants (n=37).  (B) Cardiac output of lmna+/+ (n=15) 
and lmnadel/del mutants (n=37).  (C) Isochronal map of lmna+/+ and lmnadel/del mutants summarizing 
the regional spread of electrical activity across the atrium and into the ventricle.  The lines 
represent the positions of the action potential wavefront at 5-ms intervals.  The color scale depicts 
the timing of electrical activation (blue areas activated before red areas).  (D) Mean estimated 
conduction velocities at the atrium, AV canal, and ventricle of lmna+/+ (n=7) and lmnadel/del mutants 
(n=9).  Regions of interest was placed at middle of atrium, AV canal or ventricle.  †p<0.01 vs. 
lmna+/+ by two-tailed Student’s t-test.   
 
Figure 3 Functional properties of Nav1.5 channel and Kv11.1 channel in a patient with SCN5A 
P1824A and KCNH2 R269W.   
(A) The voltage protocol and representative whole-cell Na+ currents of the wild-type and P1824A 
Nav1.5 channels.  (B) Comparison of late Na+ currents.  The late Na+ currents were measured at the 
end of 200-ms depolarizing pulses, as shown in the inset.  (C) I–V relationships for peak currents in 
HEK293 cells transfected with wild-type (n=23) and P1824A (n=21).  *p<0.05 vs wild-type by two-
tailed Student’s t-test.  (D) The voltage protocols and the voltage dependence of steady-state fast 
inactivation and activation for wild-type (n=19 and 23) and P1824A (n=14 and 21).  (E) The voltage 
protocol and representative expressed currents in CHO-K1 cells transfected with Kv11.1 wild-type 
alone, Kv11.1 R269W, and wild-type plus R269W.  (F) I–V relationships for tail currents in CHO-K1 
cells transfected with wild-type alone (closed circle, n=19), R269W (closed square, n=17), and wild-
type plus R269W (closed triangle, n=12).  *p<0.05 vs. wild-type by one-way ANOVA, followed by a 
Bonferroni post hoc test.  (G) The voltage protocols and normalized steady-state activation and 
inactivation curves for wild-type alone (n=19, and 7), R269W (n=17 and 10), and wild-type plus 
R269W (n=12 and 9).  (H) The voltage protocol and fast and slow components of deactivation time 
constants as a function of test potentials for wild-type alone (n=17), R269W (n=19), and wild-type 
plus R269W (n=21).  The deactivation process was fit to biexponential functions.   
 
Figure 4 Computer simulation of the effects of modified kinetic behavior of Kv11.1 and Nav1.5 
currents on electrophysiological properties of human ventricular myocytes (mid-myocardial cells) 
and the electrotonic effects of atrial myocytes on pacemaker activity of peripheral sinoatrial node 
(SAN) cells in a normal subject and a patient with modified Kv11.1 and Nav1.5 currents.  
(A) Simulated action potentials (top) and the time course of IKr during action potentials (bottom) of 
ventricular mid-myocardial cell models for a normal subject and a patient with modified Kv11.1 and 
Nav1.5 currents.  The model cells were paced at 1 Hz by 1-ms stimuli of 60 pA/pF for 10 min; 
steady-state behaviors after the last stimulus are shown.  Modified inactivation/deactivation 
kinetics of KCNH2 R269W and SCN5A P1824A prolonged APD90 from 424.2 to 674.2 ms.  (B) 
Simulated effects of IKr block on action potentials of ventricular mid-myocardial cells in the normal 
subject (top) and patient (bottom). Model cells with various IKr conductance (gKr) were paced at 0.5 
Hz by 1-ms stimuli of 60 pA/pF for 10 min; steady-state behaviors after the last stimulus are shown. 
In the normal model with wild-type channels (top), 40% reduction of IKr only slightly prolonged APD90 
from 467.3 to 534.4 ms.  In contrast, in the patient model with mutant channels (bottom), only 7% 
reduction of IKr dramatically prolonged APD90 from 651.6 to 1177.5 ms and evoked early 
afterdepolarization.  (C) Simulated spontaneous action potentials and time courses of INa and IKr in 
17 
 
SAN cell models for the normal subject (left) and patient (right).  A peripheral SAN model cell was 
connected to two atrial cells with gap junction conductance (GJC) of 0–5 nS, as described 
previously23.  INa and IKr during spontaneous action potentials of the patient model with mutant 
channels are much smaller than those of the normal model.  In the normal model, increasing GJC 
(up to 5 nS), although slowing pacemaking, did not cause arrhythmic dynamics or cessation of 
spontaneous activity. In contrast, in the patient model, increasing GJC caused arrhythmic dynamics 
(skipped beat runs) at 4 nS and cessation of pacemaker activity at 5 nS. 
 
Figure 5 The functional consequence of five variants in the SCN10A gene assessed by whole-cell 
patch clamp recording 
(A) The voltage protocol and representative current traces of Nav 1.8 using wild-type and mutant 
channels.  (B) I–V relationships for peak currents in ND 7/23 cells transfected with SCN10A wild-
type (n=64) and five variants including G805S (n=15), R1263X (n=15), M1373R (n=19), I1482V (n=25), 
and D1819Y (n=24).  *p<0.05 or †p<0.01 vs. wild-type by one-way ANOVA, followed by a Bonferroni 
post hoc test.  (C) Normalized steady-state activation curves of SCN10A wild-type (n=64), and three 
variants including G805S (n=15), I1482V (n=25), and D1819Y (n=24).  (D) The voltage protocols and 
normalized steady-state inactivation curves of SCN10A wild-type (n=33) and three variants including 
G805S (n=13), I1482V (n=23), and D1819Y (n=22). 
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Table 1 Clinical characteristics of patients with early-onset cardiac conduction system diseases 
Number of probands 23 
Female (%) 12 (52) 
Age at diagnosis (years) 40 ± 16 
HR (bpm) 44 ± 12 
Sick sinus syndrome (%) 13 (57) 
 R-S I/R-S II/R-S III 4/7/2 
Atrioventricular block (%) 17 (74) 
 I/II/III 2/5/10 
Family history of PMI 13 (57) 
PMI (%) 18 (78) 
Atrial fibrillation 12 (52) 
LVEF (%) 66 ± 10 
Muscular dystrophy 2 (10) 
HR, heart rate; R-S, Rubenstein;  
PMI, pacemaker implantation;  
LVEF, left ventricular ejection fraction 
 
Table 1
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Table 2 Pathogenic or likely pathogenic variants determined by 2015 ACMG standards and guidelines 
Gene Base 
change 
Amino acid 
change 
PVS1 PS2 PS3 PM2 PP1 PP3 PP5 BS3 Classification without 
PS3 (functional studies) 
Classification with PS3 
(functional studies) 
Patient 
number 
EMD 677 G>A W226X ✓   ✓ ✓ ✓ ✓  Pathogenic Pathogenic 1 
 664C>T Q222X ✓ ✓  ✓  ✓   Pathogenic Pathogenic 2 
LMNA 339dupT K114XfsX1 ✓  ✓ ✓  ✓   Pathogenic Pathogenic 3 
 1489-2A>G  ✓   ✓  ✓ ✓  Pathogenic Pathogenic 4 
 961C>T R321X ✓   ✓  ✓ ✓  Pathogenic Pathogenic 5 
KCNA5 1580C>T T527M   ✓   ✓ ✓  Uncertain significance Likely pathogenic 6 
KCNH2 805C>T R269W   ✓ ✓  ✓ ✓  Uncertain significance Likely pathogenic 7 
SCN5A 5470C>G P1824A   ✓ ✓  ✓ ✓  Uncertain significance Likely pathogenic 7 
HCN4 2845C>T R949W      ✓   Uncertain significance Uncertain significance 4 
SCN10A 3787C>T R1263X   ✓ ✓  ✓   Uncertain significance Likely pathogenic 6 
 4444A>G I1482V   ✓ ✓  ✓   Uncertain significance Likely pathogenic 8 
 5455G>T D1819Y    ✓  ✓  ✓ Uncertain significance Uncertain significance 9 
 4118T>G M1373R   ✓ ✓  ✓   Uncertain significance Likely pathogenic 9 
 1519T>C F507L    ✓  ✓   Uncertain significance Uncertain significance 10 
 2413G>A G805S   ✓ ✓  ✓   Uncertain significance Likely pathogenic 10 
RYR2 2300C>G S767W      ✓   Uncertain significance Uncertain significance 11 
MYH6 3347G>A R1116H      ✓   Uncertain significance Uncertain significance 12 
 3755G>A R1252Q    ✓  ✓   Uncertain significance Uncertain significance 12 
MYH7 968T>C I323T    ✓  ✓   Uncertain significance Uncertain significance 10 
MYH11 4532G>A R1511Q    ✓  ✓   Uncertain significance Uncertain significance 3 
RBM20 3545G>A R1182H      ✓ ✓  Uncertain significance Uncertain significance 13 
 3649G>A G1217R      ✓   Uncertain significance Uncertain significance 6 
TTN 70264G>C G23422R      ✓   Uncertain significance Uncertain significance 14 
DES 556G>A D186N    ✓  ✓   Uncertain significance Uncertain significance 14 
CBS 1552T>C Y518H    ✓  ✓   Uncertain significance Uncertain significance 4 
TBX5 409G>A V137M      ✓   Uncertain significance Uncertain significance 7 
Table 2
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PVS1: null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or multiexon deletion) in a gene where LOF is a known 
mechanism of disease. 
PS2: De novo (both maternity and paternity confirmed) in a patient with the disease and no family history. 
PS3: Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product. 
PM2: Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation 
Consortium. 
PP1: Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease. 
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product. 
PP5: Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation. 
BS3: Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing. 
 
ACMG, the American College of Medical Genetics and Genomics; AMP, the Association for Molecular Pathology; CAP, the College of American Pathologists; 
NA, not available; D, rare damaging variants; DM, disease causing mutation; EDMD, Emery-Dreifuss muscular dystrophy; DCM, dilated cardiomyopathy, AF, 
atrial fibrillation; LQTS, long QT syndrome, HCM, hypertrophic cardiomyopathy; VUS, variant of unknown significance. 
 
ACTC1 710C>T S237F    ✓  ✓   Uncertain significance Uncertain significance 8 
PRKAG2 1366C>G R456G      ✓   Uncertain significance Uncertain significance 13 
MAP2K2 937C>T R313W    ✓  ✓   Uncertain significance Uncertain significance 3 
1 
 
Table 3 Summary of clinical characteristics and detected rare mutations of patients with early-onset CCSD 
Patient 
number 
Gender Age at 
diagnosis (yrs.) 
SSS AV 
block 
FH of 
PMI 
PMI AF LVEF 
(%) 
Rare variants Classification with PS3 
(functional studies) 
1 Male 33 － ✓ ✓ ✓ ✓ 53 EMD W226X Pathogenic 
2 Male 17 － ✓ － ✓ ✓ 60 EMD Q222X Pathogenic 
3 Female 39 ✓ ✓ ✓ ✓ ✓ 58 
LMNA K114XfsX1 
MAP2K2 R313W 
MYH11 R1511Q 
Pathogenic 
4 Male 23 ✓ ✓ ✓ ✓ ✓ 64 
LMNA 1489-2A>G 
CBS Y518H 
HCN4 R949W 
Pathogenic 
5 Female 44 － ✓ ✓ ✓ ✓ 61 LMNA R321X Pathogenic 
6 Male 51 ✓ － － ✓ ✓ 70 
KCNA5 T527M 
SCN10A R1263X 
RBM20 G1217R 
Likely pathogenic 
Likely pathogenic 
7 Female 47 ✓ ✓ ✓ ✓ － 77 
SCN5A P1824A 
KCNH2 R269W 
TBX5 V137M 
Likely pathogenic 
Likely pathogenic 
8 Female 42 ✓ ✓ ✓ ✓ ✓ 79 
SCN10A I1482V 
ACTC1 S237F 
Likely pathogenic 
9 Female 31 － ✓ － ✓ － 76 
SCN10A D1819Y 
SCN10A M1373R 
 
Likely pathogenic 
10 Male 17 ✓ － － ✓ － 60 
SCN10A F507L  
SCN10A G805S 
MYH7 I323T 
 
Likely pathogenic 
CCSD, cardiac conduction system diseases; SSS, sick sinus syndrome; AV block, atrioventricular block; FH, family history; PMI, pacemaker implantation; AF 
atrial fibrillation; LVEF, left ventricular ejection fraction; underlined and bold rare variants indicate pathogenic variants.  
Table 3
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Table 4 The evaluation of cardiac function at 48 hpf and conduction velocity at 72 hpf of the F2 embryos 
 lmna +/+  lmna del/del  
Cardiac function n=15 n=37 
HR (bpm) 145 ± 11 127 ± 15† 
Stroke volume (nl) 0.39 ± 0.18 0.59 ± 0.15† 
Cardiac output (nl/min) 54.97 ± 22.85 74.35 ± 19.70† 
Fractional area change (%) 26.88 ± 8.72 38.87 ± 9.26† 
Conduction velocity n=7 n=9 
Atrium (mm/sec) 3.86 ± 0.64 3.07 ± 0.30 
Atrioventricular canal (mm/sec) 0.75 ± 0.12 0.40 ± 0.02† 
Ventricle (mm/sec) 7.99 ± 0.81 4.23 ± 0.68† 
†P<0.01 vs. lmna 
Table 4
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Table 5 Biophysical properties of wild-type and P1824A Nav1.5 channels, and wild-type and R269W Kv11.1 channels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SF, Slope factor; *P<0.05 vs. wild-type 
 
  Nav1.5 Kv11.1 
  
Wild-type P1824A Wild-type R269W 
Wild-type 
/R269W 
Cells (n)  23 21 19 17 12 
Peak INa (pA/pF) -1485  186 -846  131* — — — 
The maximum tail current (pA/pF) — — 84.2  11.2 41.3  7.4* 75.7  18.7 
Activation 
V1/2 (mV) -49.5 ± 1.1 -43.8 ± 1.7* 3.8  1.8 0.5  2.3 3.9  2.1 
SF (mV) 1.8 ± 0.2 3.4 ± 0.5* 7.9  0.3 8.7  0.4 8.5  0.4 
Cells (n)  19 14 7 10 9 
Inactivation 
V1/2 (mV) -75.9   1.2 -76.6  1.9 -50.1  4.5 -80.8  8.6* -63.0  4.8 
SF (mV) 5.1  0.1 5.4  0.1 20.9  1.9 21.7  1.7 19.7 0.7 
Cells (n)  — — 17 19 21 
Deactivation 
τfast, -80 (ms) — — 83.4  10.6 162.3  32.8 121.0  16.2 
τslow, -80 (ms) — — 514.0  58.4 907.6  166.2 747.0  163.1 
Table 5
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Table 6 Biophysical properties of wild-type, G805S, R1263X, M1373R, I1482V, and D1819Y Nav1.8 channels 
  Wild-type G805S R1263X M1373R I1482V D1819Y 
Cells (n) 64 15 15 19 25 24 
Peak INa (pA/pF) -101.0 ± 8.9 -49.2 ± 9.5 -4.5 ± 0.4* -4.8 ± 0.5* -162.9 ± 30.3† -63.3± 9.9 
Activation 
V1/2 (mV) 9.8 ± 2.3 16.2 ± 3.8 — — 0.9 ± 3.0* 12.2 ± 3.0 
SF (mV) -8.9 ± 0.3 -8.7 ± 0.4 — — -8.2 ± 0.4 -9.6 ± 0.4 
Cells (n) 33 13   23 22 
Inactivation 
V1/2 (mV) -71.7 ± 1.0 -67.2 ± 1.1* — — -70.2 ± 1.2 -71.6 ± 1.7 
SF (mV) 10.0 ± 0.3 9.6 ± 0.4 — — 9.2 ± 0.3 9.5 ± 0.3 
SF, Slope factor; *P<0.05 vs. wild-type; †P<0.01 vs. wild-type 
 
Table 6
ATarget sequencePAMTarget sequence
Exon 1
Human LMNA:     GAGCGCGCCCGCCTGCAGCTGGAGCTGAGCAAAGTGCGTGAGGAGTTTAAGGAG
Zebrafish lmna: GAACGAGCCAGACTGCAACTGGAGCTCAGCAAAGTGCGTGAGGACTACAAGGAG
                ** ** *** * ***** ******** ***************** *  ****** 
LMNA c.339dupT, p. K114XfsX1
PAMTarget sequence DSB
B
CTGCAACTGGAGCTCAGCAAAGTGCGTGAGGACTACAAGGAG CTGCAACTGGAGCTCAGCAAAGTGAGGACTACAAGGAG
DSB
PAM
lmna c. 316_319 del GTGC, p. E108TfsX5
1000 μm1000 μm
lmna del/del  (F2)lmna +/+ (F2)
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Supplementary methods 
Study patients 
The study conformed with the principles outlined in the Declaration of Helsinki and was approved by 
the Ethics Committee for Medical Research at our institution.  All study patients provided written 
informed consent before registration. 
The study patients were recruited from multiple hospitals in Japan.  Early-onset cardiac 
conduction system disease (CCSD) was defined as bradyarrhythmia occurring in individuals aged <65 
years, who showed an atrioventricular (AV) block and/or a sick sinus syndrome (SSS) with pacemaker 
implantation (PMI) or a family history of PMI.  AV block was defined as one of the following 
conditions: (1) every atrial impulse conducted to the ventricles, regular rate, but the PR interval 
exceeds 0.20 s (first-degree AV block), (2) blocking of some atrial impulses conducted to the ventricle 
at a time when physiological interference is not involved (second-degree AV block), or (3) no atrial 
activity is conducted to the ventricles (third-degree AV block).  Sick sinus syndrome was defined as 
one of the following conditions: (1) persistent spontaneous sinus bradycardia not caused by drugs 
and inappropriate for the physiological circumstance, (2) sinus arrest or exit block, (3) combinations 
of sinoatrial (SA) and AV conduction disturbances, or (4) alternation of paroxysms of rapid regular or 
irregular atrial tachyarrhythmias and periods of slow atrial and ventricular rates.  In addition, we 
used the DNA sequencing data of 102 control subjects without electrocardiogram abnormality. 
 
DNA isolation and whole-exome DNA sequencing 
Genomic DNA was extracted from peripheral blood leukocytes by using standard methods1.  Five 
micrograms of genomic DNA of the patients was submitted to TAKARA BIO INC. (Kusatsu, Shiga, 
Japan) for whole-exome sequencing (WES).  Exome capture was completed with SureSelect Human 
All Exon V5 + mtDNA (Agilent, Santa Clara, CA, USA).  Exome sequencing was performed using the 
Illumina HiSeq platform (Illumina, San Diego, CA, USA). We used the Borrows–Wheeler Aligner 
Maximal Exact Match algorithm to align sequencing reads to human reference genome (build 37). 
We also used the Genome Analysis Toolkit (GATK ver.3.6) to perform reads’ realignments and base 
quality recalibrations.  We set the sensitivity of the Variant Quality Score Recalibration threshold as 
99.6% and 95% for single nucleotide variants and insertions/deletions, respectively.  After the 
above standard quality control, we selected only the variants that were absent in the in-house WES 
data from 102 control individuals without early-onset CCSD.  Of those, we extracted the variants in 
117 candidate genes linked to arrhythmogenic disorders or cardiomyopathy for further analyses 
(Supplemental Table 1). 
 
Pathogenicity of candidate variants 
We interpreted the sequence variants using 2015 ACMG standards and guidelines, which provided 
criteria for the classification of pathogenic or likely pathogenic variants.2  Each pathogenic criterion 
Supplementary methods Click here to access/download;Supplementary Material -
Other;Supplementtal methods revised.docx
2 
 
is weighted as very strong (PVS1), strong (PS1–4), moderate (PM1–6), or supporting (PP1–5).  Rare 
variants were defined as those with minor allele frequency <0.5% in East Asian at the Human Genetic 
Variation Database (HGVD) version 2.3 and the Genome Aggregation Database (gnomAD) version 
2.0.2.  Variants which were absent from these databases were considered as PM2.  We selected 
protein-truncating variants (PTVs) in known genes associated with CCSD (PVS1), or rare missense 
variants registered as pathogenic or disease-causing mutation associated with CCSD in disease 
database including ClinVar and Human Gene Mutation Database (HGMD) (PP5).  All variants were 
annotated by the Variant Effect Predictor version 82 and referred following in silico damaging scores: 
MetaSVM for missense variants; LOFTEE for PTVs; and CADD for all variants.3  MetaSVM score 
incorporated 10 scores (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, GERP++, MutationTaster-2, 
Mutation Assessor, FATHMM, LRT, SiPhy, PhyloP) and the maximum frequency observed in 1000 
genome populations.  We used the MetaSVM scores from dbNSFP ver.2.9.1. 4  CADD score of 15 
indicated that the variant is predicted to be among the 15% most deleterious substitutions that can 
occur in the human genome.  When multiple lines of these in silico prediction algorithms supported 
a deleterious effect on the gene, the supporting pathogenic evidence of PP3 was assigned.  We 
further sought to determine the relationship between the clinical phenotype (bradyarrhythmia) and 
the genotype for probands and their relatives in whom a variant was identified (PP1 or PP4).  These 
segregation analyses were performed in the family members as much as possible.  If the missense 
variants are common causes of the disorder and the gene also has very few benign variants, then a 
missense variant in this gene can be supporting evidence for pathogenicity (PP2).  Functional 
studies were performed using cellular electrophysiological analysis, mathematical modeling, and 
simulations, and CRISPR/Cas9 mediated gene knock-out in zebrafish to confirm the pathogenicity of 
detected variants (PS3 or BS3).  For a given variant, we selected the criteria based on the evidence 
observed for the variant.  The criteria then are combined according to the scoring rules to choose a 
classification from the five-tier system2. 
 
CRISPR-mediated deletions of the human LMNA ortholog, lmna, in zebrafish 
All zebrafish experiments have been approved by Institutional Animal Care and Use Committee 
(protocol# BWH 2016N000276), which is certified by the Association for Assessment and 
Accreditation of Laboratory Animal Care.  Zebrafish euthanasia was performed following NIH 
(https://oacu.oir.nih.gov/animal-research-advisory-committee-guidelines) and American Veterinary 
Medical Association guidelines using an overdose of Tricaine (M-222 or 3-aminobenzoic acid ethyl 
ester) in combination with hypothermic shock.  
The gene editing in zebrafish with CRISPR/Cas9 was conducted to evaluate detected PTV in the 
LMNA gene from patients with early-onset CCSD.  The target site of the human LMNA ortholog, 
lmna, in zebrafish was selected using a CHOPCHOP webtool, which ranks target sites based on 
potential off-target effects (5’-GGAGCTCAGCAAAGTGCGTG-3’).  Single guide (sg) RNA was 
generated by in vitro transcription from oligonucleotide-based templates with a MEGAshortscript™ 
T7 Transcription Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA).  DNA double-strand breaks 
(DSBs) introduced by CRISPR at the target site can be repaired through error-prone nonhomologous 
end-joining (NHEJ) pathway.  The DSB repair by NHEJ could generate indel mutations, which can 
cause frame shift and then abolish gene function if the mutations occur in an exon.  Two microliters 
of sgRNA stock (400 ng/μl) was mixed with 2 μl of recombinant Cas9 protein (1 μg/μl) (PNA Bio, 
Newbury Park, CA, USA) and 2μl of water, then incubated on ice for 5 min to allow formation of the 
sgRNA/Cas9 complex.  One nanoliter of the injection mix was injected intracellularly in one-cell 
stage zebrafish embryos by using glass needles and a micromanipulator.  Zebrafish embryos were 
maintained in E3 water at 28°C.   
Cardiac phenotypes were scored at 48 and 72 hpf, and genomic DNA was prepared from 10 
individuals for Sanger sequencing.  The heart rate was visually counted at 48 hpf by using a 
stereomicroscope.  Cardiac function was evaluated at 48 hpf by using video microscopy with an 
Axioplan (Zeiss) upright microscope.  816 flames (magnification, 10×; frame rate, 250/s) were 
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captured, and sequential still frames were analyzed by Image J.  Voltage mapping was recorded on 
isolated 72 hpf zebrafish hearts 5.  Dissected hearts were stained with FluoVolt (Thermo Fisher 
Scientific Inc., Waltham, MA, USA) and immobilized with blebbistatin or Cytochalasin D (Sigma-
Aldrich, St. Louis, MO, USA) for the measurement of action potentials.  Fluorescence intensities 
were recorded with a high-speed charge coupled-device camera (RedShirtImaging, Decatur, GA, 
USA).  Acquired fluorescence images were exported as tiff stacks and analyzed using Matlab 
software (Mathworks, Natick, MA, USA). 
Mosaic founders (F0) were raised and outcrossed to a wild-type line at the age of 3 months.  
Sequencing analysis of F1 fish after outcross was performed at the age of 5 months, and various 
truncating indels of lmna gene were confirmed.  Heterozygous F1 fishes with same lmna mutation 
were incrossed, and cardiac phenotypes for F2 embryos were evaluated as stated above.  Each F2 
embryo was genotyped after evaluation of the cardiac phenotype to distinguish between 
heterozygous and homozygous carriers. 
 
Plasmid constructs and transfection of mammalian cell lines 
The KCNH2 cDNA in the mammalian expression vector pSI, the SCN5A cDNA in the pCGI vector 6, 
SCN1B cDNA in the IRGFP vector, and the SCN10A cDNA in the pIRES2-EGFP plasmid were kindly 
provided by Dr. Sabina Kupershmidt and Dr. Dan Roden (Vanderbilt University).  Mutant cDNAs 
were constructed by an overlap extension strategy or using a QuikChange XL Site-Directed 
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA).  With regard to the study of Nav1.5 
current, HEK293 cells were transiently transfected with wild-type SCN5A cDNA (0.5 μg), or mutant 
SCN5A cDNA (0.5 μg), using a FuGENE 6 Transfection Reagent (Roche Applied Science, Penzberg, 
Germany).  Cells were cotransfected with the same amount of SCN1B cDNA in the IRGFP vector as 
each sodium channel cDNA.  With regard to the studies of Kv11.1 current, CHO-K1 cells were 
transiently transfected with wild-type KCNH2 cDNA (0.5 μg) or mutant KCNH2 cDNA (0.5 μg), using a 
FuGENE 6 Transfection Reagent (Roche Applied Science, Penzberg, Germany).  Cells were 
cotransfected with the same amount of green fluorescent protein (GFP) as each potassium channel 
cDNA.  With regard to the study of Nav1.8 current, ND 7/23 cells were transiently transfected with 
3 μg of the cDNA encoding human wild-type or variant Nav1.8, using an X-tremeGENE 9 DNA 
Transfection Reagent (Roche Applied Science, Penzberg, Germany).  ND 7/23 cells were kindly 
provided by Dr. Naomasa Makita (Nagasaki University).  Cells displaying green fluorescence 48–72 h 
after transfection were subjected to electrophysiological analysis. 
 
Electrophysiology and data analysis 
Potassium or sodium currents were studied using the whole-cell patch clamp technique with an 
amplifier, Axopatch-200B (Molecular Devices, Sunnyvale, CA), at room temperature (23°C-25°C for 
potassium currents and 20°C–22C for sodium currents).  Electrode resistance ranged from 2 to 4 
M and from 0.8 to 1.5 M for potassium and sodium channel recordings, respectively. The voltage 
clamp protocols are described in the Figures.  Data were acquired using pCLAMP software (v. 9; 
Molecular Devices, Sunnyvale, CA, USA).  Data acquisition and analysis were performed using a 
Digidata 1321 A/D converter and pCLAMP8.2 software (Molecular Devices, Sunnyvale, CA, USA).  
While recording potassium currents, the pipette solution (intracellular solution) contained 110 mM 
KCl, 5 mM K2ATP, 2 mM MgCl2, 10 mM HEPES, and 5 mM K4BAPTA at pH 7.2, and the bath solution 
contained 140 mM NaCl, 5.4 mM KCl, 2 mM CaCl2, 1.0 mM MgCl2, 10 mM HEPES, and 10 mM 
glucose, adjusted to pH 7.4 with NaOH.  While recording Nav1.5 currents, the pipette solution 
(intracellular solution) contained 10 mM NaF, 110 mM CsF, 20 mM CsCl, 10 mM EGTA, and 10 mM 
HEPES at pH 7.35 with CsOH.  The bath solution contained 145 mM NaCl, 1.5 mM CaCl2, 4.5 mM 
KCl, 1 mM MgCl2, 10 mM HEPES, and 5 mM glucose, adjusted to pH 7.4 with CsOH.    While 
recording Nav1.8 currents, the pipette solution (intracellular solution) contained 10 mM NaF, 110 
mM CsF, 20 mM CsCl, 5 mM EGTA, 10 mM HEPES, and 5 mM Mg2-ATP, with a pH of 7.3 adjusted with 
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CsOH.  The bath solution contained 135 mM NaCl, 1.8 mM CaCl2, 1.0 mM MgCl2, 20 mM TEA-Cl, 10 
mM HEPES, and 10 mM glucose, with a pH of 7.4, adjusted with NaOH. Endogenous tetrodotoxin 
(TTX)-sensitive INa and L- and T-type calcium currents were eliminated with TTX 200 nM, nisoldipine 1 
μM and NiCl2 200 μM, respectively. 
The voltage dependence of potassium current activation was determined for each cell by 
fitting peak values of tail current (Itail) versus test potential to a Boltzmann function in the following 
form: Itail=Itail-max/｛1+ exp[(V1/2 − Vt) / k]｝, where Itail-max is peak Itail, Vt is the test potential, V1/2 is the 
voltage at which Itail is half of Itail-max, and k is the slope factor 7.  Steady-state inactivation of the 
potassium current was analyzed as previously described8.  Briefly, the corrected steady-state 
inactivation curves were fitted with a Boltzmann function in the following form: I/(Ima − Imin) = 1/｛1+ 
exp[(Vt − V1/2) / k]｝ + Imin, where I is the amplitude of the inactivating current corrected for 
deactivation, Imax is the maximum of I, Imin is the minimum of I, Vt is the prepulse of test potential, V1/2 
is the voltage at which I is half of Imax, and k is the slope factor.  Deactivation rates of Kv11.1 
channels were measured using a two-step voltage protocol and by fitting tail currents with two 
exponential functions 7. 
The parameters for voltage dependence of sodium current activation were estimated from the 
currentvoltage relationship based on the Boltzmann equation in the following form: 
I = Gmax × (V − Vrev) × (1 + exp[V − V1/2]/k)–1, where I is the peak Na current during the test pulse 
potential V.  The parameters estimated by the fitting are Gmax (maximum conductance), Vrev 
(reversal potential), and k (slope factor) 9.  Steady-state availability for fast inactivation was 
measured with a standard double-pulse protocol, and the data were fit with the Boltzmann equation 
in the following form: I/Imax = (1 + exp[(V − V1/2)/k])–1, where Imax is the maximum peak Na current, to 
determine the membrane potential for V1/2 and k 9. 
 
Mathematical modeling and simulations 
With mathematical models of human ventricular myocytes 10 and rabbit peripheral sinoatrial node 
(SAN) cells 11, the effects of the changes in kinetic behavior of IKr and INa on the mid-myocardial action 
potential configuration of the ventricular myocyte model and pacemaker activity of the peripheral 
SAN cell model connected to the atrial membrane model via the gap junction conductance were 
evaluated.  Dynamic behaviors of the model cell were determined by solving a system of nonlinear 
ordinary differential equations numerically.  Numerical integration was performed on Workstation 
HP xw9400 with MATLAB 7.5 (The MathWorks, Inc., Natick, MA, USA).  The numerical algorithms 
available as a MATLAB ODE solver, ode15s (a variable time-step numerical differentiation approach 
selected for its suitability to stiff systems) were used. 
 
Statistical analysis  
Pooled electrophysiological data were expressed as mean±standard error.  Two-tailed Student’s t-
test was used for single comparisons between two groups.  One-way ANOVA, followed by a 
Bonferroni post hoc test, was used to analyze data with equal variance among three or more groups.  
A value of P<0.05 was considered statistically significant. Statistical analysis was performed using JMP 
Pro 11.0.0 (SAS Institute Inc., NC, USA) and Origin 2018 (OriginLab, Northampton, MA, USA). 
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Supplemental Figure Legends 
 
Supplemental Figure 1. Generation of patient-specific mutant lines in zebrafish using CRISPR-
mediated deletions of the human LMNA ortholog, lmna, in zebrafish.   
 
Supplemental Figure 2. Functional studies of PTV, LMNA c.339dupT using CRISPR-mediated 
deletions of the human LMNA ortholog, lmna, in zebrafish .   
(A) CRISPR/ Cas9-edited embryo at 48 hpf and Sanger sequence of lmna gene.  (B) Heart rate of 
CRISPR/Cas9-injected embryos (n=66), CRISPR-only injected embryos (n=37), and non-injected 
embryos (n=61).  †P<0.01 vs. Crispr only or non-injected by one-way ANOVA, followed by a 
Bonferroni post hoc test.  (C) Isochronal map of CRISPR/ Cas9 - edited embryo and CRISPR only 
injected embryos summarizing the regional spread of electrical activity across the atrium and into 
the ventricle.  The lines represent the positions of the action potential wavefront at 5-ms intervals.  
Mean estimated conduction velocities of ventricle from CRISPR/ Cas9 - edited embryo with indels of 
lmna gene.  †P<0.01 vs. CRISPR only by two-tailed Student’s t-test.  PAM, protospacer adjacent 
motif 
 
  
6 
 
Supplemental References 
1. Nomura A, Tada H, Teramoto R, Konno T, Hodatsu A, Won HH, Kathiresan S, Ino H, Fujino N, 
Yamagishi M, Hayashi K. Whole exome sequencing combined with integrated variant 
annotation prediction identifies a causative myosin essential light chain variant in hypertrophic 
cardiomyopathy. J Cardiol. 2016;67:133-139. 
2. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector 
E, Voelkerding K, Rehm HL, Committee ALQA. Standards and guidelines for the interpretation 
of sequence variants: a joint consensus recommendation of the American College of Medical 
Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 
2015;17:405-424. 
3. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of 
genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 
2010;26:2069-2070. 
4. Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human non-synonymous SNVs and their 
functional predictions and annotations. Hum Mutat. 2013;34:E2393-2402. 
5. Panakova D, Werdich AA, Macrae CA. Wnt11 patterns a myocardial electrical gradient through 
regulation of the L-type Ca(2+) channel. Nature. 2010;466:874-878. 
6. Fukuda K, Davies SS, Nakajima T, Ong BH, Kupershmidt S, Fessel J, Amarnath V, Anderson ME, 
Boyden PA, Viswanathan PC, Roberts LJ, 2nd, Balser JR. Oxidative mediated lipid peroxidation 
recapitulates proarrhythmic effects on cardiac sodium channels. Circ Res. 2005;97:1262-1269. 
7. Hayashi K, Shimizu M, Ino H, Yamaguchi M, Mabuchi H, Hoshi N, Higashida H. Characterization 
of a novel missense mutation E637K in the pore-S6 loop of HERG in a patient with long QT 
syndrome. Cardiovasc Res. 2002;54:67-76. 
8. Smith PL, Baukrowitz T, Yellen G. The inward rectification mechanism of the HERG cardiac 
potassium channel. Nature. 1996;379:833-836. 
9. Makita N, Behr E, Shimizu W, et al. The E1784K mutation in SCN5A is associated with mixed 
clinical phenotype of type 3 long QT syndrome. J Clin Invest. 2008;118:2219-2229. 
10. Kurata Y, Hisatome I, Matsuda H, Shibamoto T. Dynamical mechanisms of pacemaker 
generation in IK1-downregulated human ventricular myocytes: insights from bifurcation 
analyses of a mathematical model. Biophys J. 2005;89:2865-2887. 
11. Kurata Y, Matsuda H, Hisatome I, Shibamoto T. Regional difference in dynamical property of 
sinoatrial node pacemaking: role of na+ channel current. Biophys J. 2008;95:951-977. 
 
 
1 
 
Supplemental Table 1 CCSD candidate 117 genes linked to arrhythmogenic diseases or 
cardiomyopathies 
ABCC9 COL3A1 ILK MAP2K1 PRKAG2 TBX5 
ACTA2 CRYAB JPH2 MAP2K2 PTPN11 TCAP 
ACTC1 CSRP3 JUP MOG1 RAF1 TGFB3 
ACTN2 DES KCNA5 MYBPC3 RBM20 TGFBR1 
AKAP9 DMD KCND3 MYH6 RYR2 TGFBR2 
ANKB DMPK KCNE1 MYH7 SCN10A TMEM43 
ANKRD1 DSC2 KCNE2 MYH11 SCN1B TMPO 
BAG3 DSG2 KCNE3 MYL2 SCN2B TNNC1 
BRAF DSP KCNE5 MYL3 SCN3B TNNI3 
CACNA1C EMD KCNH2 MYLK SCN4B TNNT2 
CACNA2D1 EYA4 KCNJ2 MYLK2 SCN5A TPM1 
CALM1 FBN1 KCNJ3 MYO6 SGCD TRDN 
CALM2 FBN2 KCNJ5 MYOZ2 SHOC2 TRPM4 
CALM3 FXN KCNJ8 MYPN SLAMP TTN 
CALR3 GJA1 KCNN2 NEXN SLC2A10 TTR 
CASQ2 GJA5 KCNQ1 NKX2.5 SLC8A1 TXNRD2 
CAV3 GLA KRAS NRAS SMAD3 VCL 
CBL GPD1L LAMP2 PDLIM3 SNTA1  
CBS HCN4 LDB3 PKP2 SOS1  
CMK2D HRAS LMNA PLN TAZ  
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Supplemental Table 2 Overview of detected rare variants of patients with early-onset CCSD 
Gene Base change Amino acid 
change 
gnomAD 
(East Asian) 
HGVD 
(JPN) 
MetaSVM CADD 
Score 
LOFTEE Novelty (ClinVar) Novelty (HGMD) 
EMD 677 G>A W226X NA NA NA 39 HC Not registered DM for EDMD 
 664C>T Q222X NA NA NA 37 HC Not registered Not registered 
LMNA 339dupT K114XfsX1 NA NA NA 34 HC Likely pathogenic Not registered 
 1489-2A>G  NA NA NA 24.9 HC Not registered DM for cardiac disease 
 961C>T R321X NA NA NA 37 HC Pathogenic DM for DCM 
KCNA5 1580C>T T527M 0.0016 0.0017 D 25.2 NA Uncertain significance DM for AF+SSS 
KCNH2 805C>T R269W NA NA D 27.2 NA Not provided DM for LQTS+SSS 
SCN5A 5470C>G P1824A NA NA D 24.6 NA Not provided DM for LQTS+SSS 
HCN4 2845C>T R949W 0.0010 0.0016 D 23.2 NA Not registered Not registered 
SCN10A 3787C>T R1263X NA NA NA 48 HC Not registered Not registered 
 4444A>G I1482V NA NA D 19.0 NA Not registered Not registered 
 5455G>T D1819Y NA NA D 31 NA Not registered Not registered 
 4118T>G M1373R NA NA D 28.2 NA Uncertain significance Not registered 
 1519T>C F507L NA NA D 22.4 NA Not registered Not registered 
 2413G>A G805S NA NA D 32 NA Not registered Not registered 
RYR2 2300C>G S767W NA 0.0004 D 34 NA Not registered Not registered 
MYH6 3347G>A R1116H 0.000065 0.0004 D 28 NA Uncertain significance Not registered 
 3755G>A R1252Q NA NA D 27.3 NA Not registered Not registered 
MYH7 968T>C I323T NA NA D 24.1 NA Uncertain significance VUS for HCM 
MYH11 4532G>A R1511Q NA NA D 34 NA Not registered Not registered 
RBM20 3545G>A R1182H 0.0022 0.0008 D 34 NA Conflicting 
interpretations of 
pathogenicity 
DM for DCM 
 3649G>A G1217R NA 0.0008 D 28.3 NA Uncertain significance Not registered 
TTN 70264G>C G23422R 0.00012 0.0004 D 22.3 NA Not registered Not registered 
DES 556G>A D186N NA NA D 24.7 NA Not registered Not registered 
CBS 1552T>C Y518H NA NA D 17.9 NA Not registered Not registered 
TBX5 409G>A V137M NA 0.0004 D 32 NA Not registered Not registered 
Supplementary table 2 Click here to access/download;Supplementary Material - Other;Supplementary table 2.docx
2 
 
 
gnomAD, Genome Aggregation Database; HGVD, Human Genetic Variation Database; MetaSVM, in silico ensemble damaging score; CADD, combined 
annotation dependent depletion; LOFTEE, loss-of-function transcript effect estimator; HGMD, human gene mutation database; NA, not available; D, rare 
damaging variants; HC, high-confidence; DM, disease causing mutation; EDMD, Emery-Dreifuss muscular dystrophy; DCM, dilated cardiomyopathy, AF, atrial 
fibrillation; LQTS, long QT syndrome, HCM, hypertrophic cardiomyopathy; VUS, variant of unknown significance. 
 
ACTC1 710C>T S237F NA NA D 29.2 NA Not registered Not registered 
PRKAG2 1366C>G R456G 0.000058 NA D 23.7 NA Not registered Not registered 
MAP2K2 937C>T R313W NA NA D 27.1 NA Uncertain significance Not registered 
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